Meeting summary: Ethical aspects of whole exome and whole genome sequencing studies (WES/WGS) in rare diseases, Tel Aviv, Israel, January 2013

Luba Farberov, Avital Gilam, Ofer Isakov, Noam Shomron*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

A recent E-Rare workshop reviewed the ethical aspects of whole exome and whole genome-sequencing studies (WES and WGS, respectively) in rare diseases. Leveraging new genomic technologies, which output vast amounts of known and novel genetic variants, researchers are learning more about the genetic basis and mechanisms involved in rare diseases. In some cases, these findings are translated into diagnostic tools for the benefit of rare disease patients. Among the disclosed data, which can assist in treatment management, incidental findings await, bringing with them ethical concerns for the clinicians, researchers and patients.

Original languageEnglish
Pages (from-to)53-56
Number of pages4
JournalGenetical Research
Volume95
Issue number2-3
DOIs
StatePublished - Jun 2013

Fingerprint

Dive into the research topics of 'Meeting summary: Ethical aspects of whole exome and whole genome sequencing studies (WES/WGS) in rare diseases, Tel Aviv, Israel, January 2013'. Together they form a unique fingerprint.

Cite this